suramin has been researched along with Leishmaniasis in 5 studies
Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.
suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.
Leishmaniasis: A disease caused by any of a number of species of protozoa in the genus LEISHMANIA. There are four major clinical types of this infection: cutaneous (Old and New World) (LEISHMANIASIS, CUTANEOUS), diffuse cutaneous (LEISHMANIASIS, DIFFUSE CUTANEOUS), mucocutaneous (LEISHMANIASIS, MUCOCUTANEOUS), and visceral (LEISHMANIASIS, VISCERAL).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, a new semi-synthetic berberine analogue, 5,6-didehydro-8,8-diethyl-13-oxodihydroberberine chloride (1), showed nanomolar level potency against in vitro models of leishmaniasis, malaria, and trypanosomiasis as well as activity in an in vivo visceral leishmaniasis model." | 3.77 | Potent antiprotozoal activity of a novel semi-synthetic berberine derivative. ( Anklin, C; Bahar, M; Deng, Y; Doskotch, RW; Drew, ME; Gil, RR; He, S; Kinghorn, AD; Navarro-Vázquez, A; Pandharkar, T; Werbovetz, KA; Zhu, X, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bahar, M | 1 |
| Deng, Y | 1 |
| Zhu, X | 1 |
| He, S | 1 |
| Pandharkar, T | 1 |
| Drew, ME | 1 |
| Navarro-Vázquez, A | 1 |
| Anklin, C | 1 |
| Gil, RR | 1 |
| Doskotch, RW | 1 |
| Werbovetz, KA | 1 |
| Kinghorn, AD | 1 |
| Khanra, S | 1 |
| Kumar, YP | 1 |
| Dash, J | 1 |
| Banerjee, R | 1 |
| Sbaraglini, ML | 1 |
| Vanrell, MC | 1 |
| Bellera, CL | 1 |
| Benaim, G | 1 |
| Carrillo, C | 1 |
| Talevi, A | 1 |
| Romano, PS | 1 |
| Figueiredo, AB | 1 |
| Serafim, TD | 1 |
| Marques-da-Silva, EA | 1 |
| Meyer-Fernandes, JR | 1 |
| Afonso, LC | 1 |
| TELLA, A | 1 |
1 review available for suramin and Leishmaniasis
| Article | Year |
|---|---|
Neglected Tropical Protozoan Diseases: Drug Repositioning as a Rational Option.
Topics: Antiprotozoal Agents; Chagas Disease; Drug Repositioning; Humans; Leishmaniasis; Neglected Diseases; | 2016 |
4 other studies available for suramin and Leishmaniasis
| Article | Year |
|---|---|
Potent antiprotozoal activity of a novel semi-synthetic berberine derivative.
Topics: Animals; Antiprotozoal Agents; Berberine; Chlorocebus aethiops; Disease Models, Animal; Inhibitory C | 2011 |
In vitro screening of known drugs identified by scaffold hopping techniques shows promising leishmanicidal activity for suramin and netilmicin.
Topics: Animals; Antiprotozoal Agents; Cell Line, Tumor; Drug Evaluation, Preclinical; Drug Synergism; Leish | 2018 |
Leishmania amazonensis impairs DC function by inhibiting CD40 expression via A2B adenosine receptor activation.
Topics: Acetamides; Adenosine A2 Receptor Antagonists; Animals; B7-2 Antigen; Bone Marrow Cells; CD40 Antige | 2012 |
CHEMOTHERAPY OF TROPICAL DISEASES.
Topics: Amebiasis; Amebicides; Anti-Bacterial Agents; Antimalarials; Antimony; Arsenicals; Chagas Disease; C | 1964 |